SEARCH

SEARCH BY CITATION

References

  • BAKHLE, Y.S. (1990). Pharmacokinetic and metabolic properties of lung. Br. J. Anaesth., 65, 7993.
  • BLANDINI, F. (2005). Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease CNS. Drug. Rev., 11, 183194.
  • BIRKMAYER, W., KNOLL, J., RIEDERER, P., YOUDIM, M.B., HARS, V. & MARTON, J. (1985). Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J. Neural. Transm., 64, 113127.
  • BIRKMAYER, W., RIEDERER, P., YOUDIM, M.B.H. & LINAUER, W. (1975). The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, L-deprenyl. J. Neural. Transm., 36, 303326.
  • BONNET, U. (2003). Moclobemide: therapeutic use and clinical studies. CNS. Drug. Rev., 9, 97140.
  • BOTTLAENDER, M., DOLLE, F., GUENTHER, I., ROUMENOV, D., FUSEAU, C., BRAMOULLE, Y., CURET, O., JEGHAM, J., PINQUIER, J.L., GEORGE, P. & VALETTE, H. (2003). Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone. J. Pharmacol. Exp. Ther., 305, 467473.
  • BOYER, E.W. & SHANNON, M. (2005). The serotonin syndrome. N. Engl. J. Med., 352, 11121120.
  • COLLINS, G.G.S., SANDLER, M., WILLIAMS, E.D. & YOUDIM, M.B.H. (1970). Multiple forms of human brain monoamine oxidase. Nature, 225, 817820.
  • COLZI, A., D’AGOSTINI, F., CESURA, A.M., BORRONI, E. & DA PRADA, M. (1993). Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J. Pharmacol. Exp. Ther., 265, 103111.
  • DAVIDSON, J.R. (2003). Pharmacotherapy of social phobia. Acta. Psychiatr. Scand., 417 (Suppl), 6571.
  • FINBERG, J.P. & TENNE, M. (1982). Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br. J. Pharmacol., 77, 1321.
  • FINBERG, J.P., TENNE, M. & YOUDIM, M.B. (1981). Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol., 73, 6574.
  • FINBERG, J.P., WANG, J., BANKIEWICZ, K., HARVEY-WHITE, J., KOPIN, I.J. & GOLDSTEIN, D.S. (1998). Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J. Neural. Transm. Suppl., 52, 279285.
  • FINBERG, J.P. & YOUDIM, M.B. (1985). Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br. J. Pharmacol., 85, 541546.
  • GAL, S., ZHENG, H., FRIDKIN, M. & YOUDIM, M.B.H. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. II; in vivo selective brain monoamine oxidase inhibition and prevention of MPTP induced striatal dopamine depletion. J. Neurochem., 95, 7988.
  • GINGRICH, J.A. (2002). Mutational analysis of the serotonergic system: recent findings using knockout mice. Curr. Drug Targets CNS Neurol. Disord., 1, 449465.
  • GREEN, A.R., MITCHELL, B.D., TORDOFF, A.F. & YOUDIM, M.B. (1977). Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol., 60, 343349.
  • GREEN, A.R. & YOUDIM, M.B. (1975). Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br. J. Pharmacol., 55, 415422.
  • GRUNBLATT, E., MANDEL, S., JACOB-HIRSCH, J., ZELIGSON, S., AMARIGLO, N., RECHAVI, G., LI, J., RAVID, R., ROGGENDORF, W., RIEDERER, P. & YOUDIM, M.B. (2004). Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm., 111, 15431573.
  • HAEFELY, W., BURKARD, W.P., CESURA, A.M., KETTLER, R., LOREZ, H.P., MARTIN, J.R., RICHARDS, J.G., SCHERSCHLICHT, R. & DA PRADA, M. (1992). Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berlin)., 106 (Suppl), S6S14.
  • HEIKKILA, R.E., MANZINO, L., CABBAT, F.S. & DUVOISIN, R.C. (1984). Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 311, 467469.
  • JOHNSTON, P. (1968). Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol., 17, 12851297.
  • KNOLL, J. & MAGYAR, K. (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol., 5, 393408.
  • MANDEL, S., WEINREB, O., AMIT, T. & YOUDIM, M.B. (2005). Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain. Res. Brain. Res. Rev., 48, 379387.
  • MELAMED, E. & YOUDIM, M.B. (1985). Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase. Br. J. Pharmacol., 86, 529531.
  • MENDLEWICZ, J. & YOUDIM, M.B.H. (1983). L-Deprenyl, a selective monoamine oxidase type B inhibitor in the treatment of depression; a double blind examination. Br. J. Psychiat., 142, 507511.
  • RIEDERER, P., SOFIC, E., RAUSCH, W.D., SCHMIDT, B., REYNOLDS, G.P., JELLINGER, K. & YOUDIM, M.B. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem., 52, 515520.
  • RIEDERER, P. & YOUDIM, M.B. (1986). Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochem., 46, 13591365.
  • ROGERS, J.T., RANDALL, J.D., CAHILL, C.M., EDER, P.S., HUANG, X., GUNSHIN, H., LEITER, L., MCPHEE, J., SARANG, S.S., UTSUKI, T., GREIG, N.H., LAHIRI, D.K., TANZI, R.E., BUSH, A.I., GIORDANO, T. & GULLANS, S.R. (2002). An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem., 277, 4551845528.
  • SAGI, Y., DRIGUES, N. & YOUDIM, M.B.H. (2005). The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br. J. Pharmacol., 146, 553560.
  • SYMES, A.L., SOURKES, T.L., YOUDIM, M.B., GREGORIADIS, G. & BIRNBAUM, H. (1969). Decreased monoamine oxidase activity in liver of iron-deficient rats. Can. J. Biochem., 47, 9991002.
  • YAMAMOTO, M. (2001). Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J. Neurol., 248 (Suppl 3:III), 511.
  • YOUDIM, M.B. & BUCCAFUSCO, J.J. (2005). Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 26, 2735.
  • YOUDIM, M.B.H., COLLINS, G.G.S., SANDLER, M., BEVAN-JONES, A.B., PARE, C.M. & NICHOLSON, W.J. (1972). Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature, 236, 225228.
  • YOUDIM, M.B.H., EDMONDSON, D. & TIPTON, K.F. (2005). Monoamine oxidases and their inhibitors. Nat. Rev. Neurosci. (in press).
  • YOUDIM, M.B.H., FINBERG, J.P.M. & TIPTON, K.F. (1988). Monoamine oxidase. In: Advances in Experimental Pharmacology. Catecholamine. II. ed. Trendelenburg, U. & Weiner, U., pp. 119192. Berlin: Springer-Verlag.
  • YOUDIM, M.B. & GREEN, A.R. (1975). Biogenic monoamine metabolism and functional activity in iron-deficient rats: behavioural correlates. Ciba. Found Symp., 51, 201225.
  • YOUDIM, M.B., GROSS, A. & FINBERG, J.P. (2001). Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol., 132, 500506.
  • YOUDIM, M.B. & WEINSTOCK, M. (2004). Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology, 25, 243250.
  • YOUDIM, M.B., MARUYAMA, W. & NAOI, M. (2005). Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiParkinsonian drug, rasagiline. Drugs Today, 41, 369391.
  • YOUDIM, M.B., WOODS, H.F., MITCHELL, B., GRAHAME-SMITH, D.G. & CALLENDER, S. (1975). Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin. Sci. Mol. Med., 48, 289295.
  • ZECCA, L., YOUDIM, M.B., RIEDERER, P., CONNOR, J.R. & CRICHTON, R.R. (2004). Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci., 5, 863873.
  • ZHENG, H., GAL, S., FRIDKIN, M., WEINER, R.L. & YOUDIM, M.B.H. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase drugs for neurodegenerative diseases: I. in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem., 95, 6878.